Pituitary ACTH Hypersecretion (Cushings Disease) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2014', provides an overview of the Pituitary ACTH Hypersecretion (Cushing's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pituitary ACTH Hypersecretion (Cushing's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pituitary ACTH Hypersecretion (Cushing's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pituitary ACTH Hypersecretion (Cushing's Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing's Disease) - Overview 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis 10
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics under Development by Companies 11
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics under Investigation by Universities/Institutes 13
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Pituitary ACTH Hypersecretion (Cushing's Disease) - Products under Development by Companies 17
Pituitary ACTH Hypersecretion (Cushing's Disease) - Products under Investigation by Universities/Institutes 18
Pituitary ACTH Hypersecretion (Cushing's Disease) - Companies Involved in Therapeutics Development 19
Corcept Therapeutics Incorporated 19
Cortendo AB 20
Cyclacel Pharmaceuticals, Inc. 21
ElexoPharm GmbH 22
Ipsen S.A. 23
Isis Pharmaceuticals, Inc. 24
Novartis AG 25
Orphagen Pharmaceuticals, Inc. 26
Pfizer Inc. 27
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AT-814 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DG-3173 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ISIS-GCCRRx - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ketoconazole - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LCI-699 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
mifepristone - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MPP-482 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pasireotide LAR - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Peptides to Antagonize ACTH Receptor for Cushing's Syndrome - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
seliciclib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Inhibit CYP11B1 for Cushing Disease and Subclinical Hypercortisolism - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit Cortisol for Metabolic Disorders - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Pituitary ACTH Hypersecretion (Cushing's Disease) - Recent Pipeline Updates 58
Pituitary ACTH Hypersecretion (Cushing's Disease) - Dormant Projects 65
Pituitary ACTH Hypersecretion (Cushing's Disease) - Product Development Milestones 66
Featured News & Press Releases 66
Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014 66
Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014 66
Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014 66
Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting 66
Jun 19, 2014: New Research on Corcept's Korlym for Patients with Cushing's Syndrome to be Presented at ICE/ENDO 2014 67
Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome 68
Apr 10, 2012: Corcept Therapeutics Launches Korlym For Patients With Endogenous Cushing's Syndrome 69
Apr 09, 2012: Corcept Announces Publication Of Phase III Trial Results Of Korlym In Journal of Clinical Endocrinology and Metabolism 69
Mar 26, 2012: Corcept Selects PharmaForm As Primary Commercial Manufacturer For Korlym 70
Mar 22, 2012: Corcept Therapeutics To Ship Korlym For Patients With Endogenous Cushing's Syndrome By April 11, 2012 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease), H2 2014 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Corcept Therapeutics Incorporated, H2 2014 19
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Cortendo AB, H2 2014 20
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 21
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by ElexoPharm GmbH, H2 2014 22
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Ipsen S.A., H2 2014 23
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 24
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Novartis AG, H2 2014 25
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 26
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Pfizer Inc., H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Pituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics - Recent Pipeline Updates, H2 2014 58
Pituitary ACTH Hypersecretion (Cushing's Disease) - Dormant Projects, H2 2014 65